📊 Statistics
- Analyst 1 Year Price Target:
-
- Upside/Downside from Analyst Target:
-
- Broker Call:
-
- Dividend Minimum 3 Year Yield:
0.00%
- EPS Growth Range (1Y):
0-10%
- Net Income Growth Range (1Y):
<0%
- Revenue Growth Range (1Y):
200-500%
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2022 |
- |
- |
- |
2022-11-07 |
- |
Ratio: 1:1
|
|
Total Amount for 2022: $0.000000 |
📅 SGX Earnings Announcements for 8YY
Biolidics Limited (8YY)
Market: SGX |
Currency: SGD
Address: 18 Howard Road
Biolidics Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions. The company operates through Cancer, Infectious Diseases, and Laboratory Services segments. It provides Covid-19 PCR testing kits. The company offers ClearCell FX1 System, an automated device that separates and enriches cancer cells from blood; and antigen and antibody test kits, as well as laboratory services. It serves academic and research institutes, hospitals, and laboratories in Singapore, China, Hong Kong, Japan, the United States, and other European Union countries. The company was incorporated in 2009 and is based in Singapore.
📈 Biolidics Limited Historical Chart
🧾 Recent Financial Statement Analysis
August 26, 2025
Embracing Future Holdings Expands into Hong Kong Esports Market with New Subsidiary: What Investors Should Know Key Points at a Glance Embracing Future Holdings Limited (formerly Biolidics Limited) has incorporated a wholly owned subsidiary in Hong Kong. The new entity,…
August 12, 2025
Embracing Future Holdings Limited: HY FY2025 Financial Analysis Embracing Future Holdings Limited (formerly Biolidics Limited) has released its unaudited interim financial statements for the six months ended 30 June 2025. The company, recently pivoting from biomedical technology to focus on…
April 10, 2025
Financial Report Analysis: Biolidics Limited Company Overview Biolidics Limited is a company incorporated in the Republic of Singapore, with a focus on providing financial services and solutions. The company operates in the biotechnology industry, and its core business operations involve…
November 2, 2024
Biolidics Limited Financial Analysis: Net Profit Decline of 20.7% Biolidics Limited Financial Analysis: Net Profit Decline of 20.7% Business Description Biolidics Limited is a Singapore-based company primarily engaged in the development, marketing, sale, and distribution of biomedical technology, life, and…
🔎 View more in SGX corporate News 🔎 View more in SGX Financial statements
📰 Related News & Research
Showing results matched by any of: 8YY.SI, Biolidics Limited, EFH Ltd, EFH SP, EMBRACING FUTURE HOLDINGS LT, EMBRACING FUTURE
August 26, 2025
Embracing Future Holdings Expands into Hong Kong Esports Market with New Subsidiary: What Investors Should Know Key Points at a Glance Embracing Future Holdings Limited (formerly Biolidics Limited) has incorporated a wholly owned subsidiary in Hong Kong. The new entity,…
August 12, 2025
Embracing Future Holdings Limited: HY FY2025 Financial Analysis Embracing Future Holdings Limited (formerly Biolidics Limited) has released its unaudited interim financial statements for the six months ended 30 June 2025. The company, recently pivoting from biomedical technology to focus on…
April 10, 2025
Financial Report Analysis: Biolidics Limited Company Overview Biolidics Limited is a company incorporated in the Republic of Singapore, with a focus on providing financial services and solutions. The company operates in the biotechnology industry, and its core business operations involve…
November 2, 2024
Biolidics Limited Financial Analysis: Net Profit Decline of 20.7% Biolidics Limited Financial Analysis: Net Profit Decline of 20.7% Business Description Biolidics Limited is a Singapore-based company primarily engaged in the development, marketing, sale, and distribution of biomedical technology, life, and…
